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BACKGROUND: Total cholesterol and high-density lipoprotein cholesterol 
(HDL-C) measurements are central to cardiovascular disease (CVD) risk 
assessment, but there is continuing debate around the utility of other lipids for 
risk prediction.
METHODS: Participants from UK Biobank without baseline CVD and not taking 
statins, with relevant lipid measurements (n=346 686), were included in the 
primary analysis. An incident fatal or nonfatal CVD event occurred in 6216 
participants (1656 fatal) over a median of 8.9 years. Associations of nonfasting 
lipid measurements (total cholesterol, HDL-C, non–HDL-C, direct and calculated 
low-density lipoprotein cholesterol [LDL-C], and apolipoproteins [Apo] A1 and B) 
with CVD were compared using Cox models adjusting for classical risk factors, 
and predictive utility was determined by the C-index and net reclassification 
index. Prediction was also tested in 68 649 participants taking a statin with or 
without baseline CVD (3515 CVD events).
RESULTS: ApoB, LDL-C, and non–HDL-C were highly correlated (r>0.90), 
while HDL-C was strongly correlated with ApoA1 (r=0.92). After adjustment 
for classical risk factors, 1 SD increase in ApoB, direct LDL-C, and non–HDL-C 
had similar associations with composite fatal/nonfatal CVD events (hazard 
ratio, 1.23, 1.20, 1.21, respectively). Associations for 1 SD increase in HDL-C 
and ApoA1 were also similar (hazard ratios, 0.81 [both]). Adding either 
total cholesterol and HDL-C, or ApoB and ApoA, to a CVD risk prediction 
model (C-index, 0.7378) yielded similar improvement in discrimination 
(C-index change, 0.0084; 95% CI, 0.0065, 0.0104, and 0.0089; 95% CI, 
0.0069, 0.0109, respectively). Once total and HDL-C were in the model, no 
further substantive improvement was achieved with the addition of ApoB 
(C-index change, 0.0004; 95% CI, 0.0000, 0.0008) or any measure of LDL-C. 
Results for predictive utility were similar for a fatal CVD outcome, and in 
a discordance analysis. In participants taking a statin, classical risk factors 
(C-index, 0.7118) were improved by non–HDL-C (C-index change, 0.0030; 
95% CI, 0.0012, 0.0048) or ApoB (C-index change, 0.0030; 95% CI, 0.0011, 
0.0048). However, adding ApoB or LDL-C to a model already containing 
non–HDL-C did not further improve discrimination.
CONCLUSIONS: Measurement of total cholesterol and HDL-C in the nonfasted 
state is sufficient to capture the lipid-associated risk in CVD prediction, with no 
meaningful improvement from addition of apolipoproteins, direct or  
calculated LDL-C.
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Hyperlipidemia has been widely documented to be associated with higher cardiovascular disease (CVD) risk,1 and pharmacological reduction of 
circulating non–high-density lipoprotein cholesterol 
(HDL-C) is beneficial in primary and secondary CVD 
prevention.2,3 Widely-used clinical CVD risk calculators 
frequently include classical biochemistry measures of 
total cholesterol, HDL-C, or a combination of these.4–7
Total cholesterol is an estimate of the cholesterol in 
all very-low-density lipoproteins, intermediate-density 
lipoproteins, low-density lipoproteins (LDL), high-densi-
ty lipoprotein, and lipoprotein(a) in the fasted state, as 
well as chylomicrons and their remnant particles in the 
unfasted state. Notably, the majority of total cholesterol 
resides in LDL particles, and the additional clinical util-
ity of recently developed direct LDL-cholesterol (LDL-C) 
measurements are not entirely clear. Non–HDL-C has 
been suggested as a pragmatic and cost-effective al-
ternative to direct LDL-C measurement, requiring only 
total cholesterol and HDL-C to be performed.8
Apolipoproteins (Apo) A1 and B are the principle 
protein components of HDL and non-HDL particles, re-
spectively, and have also been of interest for their po-
tential in improving CVD risk prediction.9,10 This is partly 
because of the proteins being key components of li-
poprotein function, and their measurement facilitating 
quantification of objective particle numbers.8 ApoB is 
thought to be of similar use in CVD prediction as non–
HDL-C and LDL-C, but in some studies has shown im-
provements in prediction in scenarios where treated 
LDL-C levels are within the normal range.11 However, 
an Emerging Risk Factor Collaboration individual par-
ticipant meta-analysis from 37 prospective cohorts (165 
544 participants) suggested that replacement of tradi-
tional lipid parameters with ApoA1 and ApoB measure-
ments only offered very modest improvement in CVD 
prediction.12,13 Despite this, enthusiasm for clinical use 
of apolipoprotein measurements beyond LDL-C or total 
cholesterol remains high in many places.14
Therefore, despite considerable research, identifica-
tion of the most informative measures of blood lipids in 
terms of CVD risk is still a matter of some contention. 
UK Biobank is a large, prospective, population-based 
cohort study that has recently released data on baseline 
biochemistry measurements including routine lipids and 
apolipoproteins in participants who consented to blood 
sample collection. Participants were generally of an age 
range where CVD risk scoring is conducted in clinical 
practice. All blood tests were conducted in a single ded-
icated ISO17025 accredited biochemistry laboratory us-
ing robust methodologies. These data therefore might 
be more robust than data from some constituent stud-
ies in previous meta-analyses and may robustly address 
controversies around biomarker utility in risk scoring. 
The aim of this study was to investigate whether ad-
ditional lipid/lipoprotein measurements improve predic-
tion of CVD events over established risk scores.
METHODS
The data reported in this article are available via application 
to the UK Biobank to other researchers for purposes of repro-
ducing the results or replicating the procedure.
UK Biobank recruited 502 639 participants (aged 37–73 
years) from 22 assessment centers across the UK between 
2007 and 2010. Baseline biological measurements were 
recorded, and touch-screen questionnaires were admin-
istered, as described elsewhere.15,16 UK Biobank received 
ethical approval from the North West Multi-Center Research 
Ethics Committee (11/NW/03820). All participants gave writ-
ten informed consent before enrollment in the study, which 
was conducted in accordance with the principles of the 
Declaration of Helsinki.
The first (of 2) measurements of systolic and diastolic 
blood pressure were used for these analyses, preferentially 
using an automated measurement. Repeated blood pres-
sure measurements were very similar and highly correlated.17 
Smoking status was categorized into never or former/current 
smoking for this analysis. Ethnicity was coded as white, black, 
South Asian, or other. Nonfasting venous blood sampling 
was conducted, and collection procedures for the study were 
validated.18 Biochemistry measures were performed at a dedi-
cated central laboratory between 2014 and 2017, including 
serum total cholesterol, HDL-C, triglycerides, direct LDL-C, 
and ApoA1 and ApoB. Non–HDL-C was calculated as total 
minus HDL-C.19 LDL-C was additionally calculated using 2 for-
mulae/schema: Friedewald and Martin/Hopkins. Friedewald 
LDL is not calculated in 10 884 patients with triglycerides 
>400 mg/dL (2.2%). In this group, a direct LDL measure-
ment was used as a substitute measure to minimize loss of 
Clinical Perspective
What Is New?
• Once total cholesterol and high-density lipoprotein 
cholesterol are included in a primary cardiovascular 
disease risk prediction score in a cohort at low risk, 
there is no evidence that addition of other lipids or 
lipoproteins (apolipoprotein B, apolipoprotein A1, 
direct or calculated low-density lipoprotein choles-
terol) appreciably improve prediction.
• Similar findings were reproduced in those taking a 
statin at baseline.
What Are the Clinical Implications?
• Calls for widespread use of apolipoproteins are 
not warranted given the negligible difference in 
risk prediction beyond total cholesterol and high-
density lipoprotein cholesterol.
• Direct low-density lipoprotein cholesterol is also 
not required for risk prediction; non–high-density 
lipoprotein cholesterol is a cheaper equivalent pre-
dictor of risk on and off statins, without require-
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data and mimics a potential clinical scenario where patients 
with a high triglycerides result may automatically have LDL 
directly measured. Remnant cholesterol was also calculated 
(Methods in the online-only Data Supplement). Further details 
of these measurements and assay performances can be found 
in the UK Biobank online showcase and protocol,20 and fur-
ther information is listed in the supplement (Methods in the 
online-only Data Supplement).
The definition of known baseline diabetes included self-
reported type 1 or type 2 diabetes (either as a stand-alone 
reported illness, or in response to a specific question about 
doctor-diagnosed diabetes) or those who reported using 
insulin. Statin and antihypertensive medication use were 
self-reported. Baseline cardiovascular disease was defined as 
self-reported historic angina, myocardial infarction, stroke, or 
transient ischemic attack.
Date and cause of death were obtained from death certifi-
cates held by the National Health Service Information Center 
for participants from England and Wales and the National 
Health Service Central Register Scotland for participants from 
Scotland. There were 2 outcomes of interest in the current 
study. The primary outcome was incident fatal and nonfatal 
cardiovascular disease that reflects the American College of 
Cardiology/American Heart Association guidelines predic-
tion score including death from cardiovascular disease as 
the underlying cause (International Classification of Diseases, 
Tenth Revision: [ICD-10]: I20–25, I60–64) or hospitalization 
for cardiovascular disease (ICD-10: I21, I22, I60–64)7 from 
Hospital Episode Statistics. A secondary outcome was death 
from cardiovascular disease as the underlying cause specifi-
cally (ICD-10: I10–15, I44–51, I20–25, I61–73) (Methods in 
the online-only Data Supplement), reflecting outcomes used 
in the European Systematic Coronary Risk Evaluation (SCORE) 
clinical guidelines.21
The period at risk per participant began on the date of 
their assessment. End of follow-up for each participant was 
recorded as the date of death or the date of end of follow-up 
for the assessment center attended (January 31, 2018, for 
assessment centers in Wales or England and November 30, 
2016, for participants in Scotland), or the first date of hospi-
talization for CVD (in outcome 1), whichever came first.
Participants with a baseline history of CVD or on statins 
were excluded from the primary analyses, but associations 
of lipids with CVD events were analyzed in this group as a 
secondary aim. All analyses were performed on those with 
complete data for exposures and covariates of interest.
Statistical Analyses
Classical risk factors were expressed as mean (SD) as all were 
approximately normally distributed, and number (%) for cat-
egorical variables. Each lipid/protein variable was also catego-
rized into quintiles. The distribution of classical risk factors 
by categories of each lipid/protein variable (total cholesterol, 
HDL-C, LDL-C, non–HDL-C, ApoA1, ApoB) were assessed 
using tests for trends across the variable using ANOVA, or a 
chi-squared test, as appropriate. Associations between clas-
sical risk factors and lipid/protein variables with CVD events 
were also tabulated using these methods.
Correlations between log-transformed total cholesterol, 
HDL-C, LDL-C, non–HDL-C, ApoA1, and ApoB were assessed 
using Pearson correlation coefficient, both without adjust-
ment, then accounting for sex and age.
Event-free survival was initially explored for each quintile 
of lipid/protein using univariable Kaplan-Meier models for 
both incident and fatal CVD. The association of each lipid/
protein variable with incident nonfatal and fatal CVD was 
tested using Cox proportional hazard models. Models for the 
incident fatal/nonfatal CVD event were adjusted for nonlipid 
variables broadly comparable to those used in the American 
College of Cardiology/American Heart Association guidelines: 
age, sex, ethnicity, systolic blood pressure, diastolic blood 
pressure, antihypertensive medication, diabetes, and smok-
ing.7 Models of fatal CVD were adjusted for nonlipid variables 
used in the European SCORE clinical guidelines: age, sex, sys-
tolic blood pressure, and smoking.21 Cox proportional haz-
ards models conducted in people who had baseline CVD or 
were taking a statin were also additionally adjusted for base-
line CVD and statin use. Follow-up time was calculated as 
days from assessment to first CVD hospital diagnosis or CVD 
death, the end of follow-up, or loss to follow-up, whichever 
occurred first. We made qualitative comparisons between the 
hazard ratios (HR) for the lipid and lipoprotein variables; fix-
ing the β coefficients for covariates in the models made no 
substantial difference to overall conclusions.
To visualize the relationship between each lipid/protein 
variable and outcome, restricted cubic splines with 4 knots (at 
the 5th, 35th, 65th, and 95th centiles22) were constructed for 
each lipid/protein variable, and the fully adjusted relationship 
(as above) with CVD events was plotted. Changing knots did 
not substantially change the shape of the associations (data 
not shown).
To assess the differential predictive ability of each lipid/pro-
tein, both alone and in combination, adjusted Cox propor-
tional hazard models were constructed for each outcome (the 
lipid/protein variable was entered linearly into the model, or 
in the case of fatal CVD, lipid/protein variables were added as 
quintiles because of nonlinearity). Potential pairwise interac-
tions between classical risk factors and lipid/protein variables 
were considered. The proportional hazard assumption was 
checked by visual inspection of Schöenfeld residuals. Utility 
of lipids to discriminate composite and fatal CVD events were 
then tested using Harrell C-statistics using an either/or model 
(testing whether a priori measurement of total and HDL-
C, or ApoB and ApoA1, is preferable) or an additive model 
(whether other lipids and lipoproteins add to total and HDL-
C). We also investigated model fit using changes in Akaike 
Information Criteria and Bayesian Information Criteria. 
We used a categorical net reclassification index, with 1000 
bootstraps to estimate 95% CI, to investigate the changes 
in predicted risk classification across the 7.5% 10-year risk 
boundary used to allocate statins in the American College of 
Cardiology/American Heart Association model.23
A discordance sensitivity analysis was also performed to 
check utility of LDL-C and apolipoprotein measurement in 
a group where ApoB and direct LDL-C were not in “agree-
ment.” The absolute difference in the percentile of ApoB and 
direct LDL for each participant was used to stratify the popu-
lation into a discordant group (those with an absolute differ-
ence of >10 percentage points between their ApoB and LDL 
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All analyses were performed using STATA 14 (StataCorp 
LP) and R3.5.1 (including package nricens25). A P value of 
<0.05 was considered statistically significant.
RESULTS
Baseline Results
Of 413 326 participants with no history of CVD or statin 
use, complete data on covariates of interest, including 
lipid/protein variables, were available in 346 686 par-
ticipants (83.9%). Data were also available in 68 649 
participants taking a statin with or without baseline 
CVD (secondary analysis).
In those with no history of CVD and not taking a 
statin, higher total cholesterol, ApoB, direct LDL-C, and 
non–HDL-C were all associated with older age, and 
higher systolic and diastolic blood pressure (Tables I 
through IV in the online-only Data Supplement). Wom-
en were more likely to have high total cholesterol levels 
(Table I in the online-only Data Supplement), whereas 
men were more likely to have high ApoB levels (Table II 
in the online-only Data Supplement). Both HDL-C and 
ApoA1 were associated with older age and were high-
er in women (Tables V and VI in the online-only Data 
Supplement). ApoB, direct and calculated LDL-C, and 
non–HDL-C were all highly correlated with each other 
(r>0.90), while HDL-C was strongly associated with 
ApoA1 (r=0.924) (Table 1).
Univariable Associations of ApoB and 
ApoA1 with CVD Outcomes
Median follow up time was 8.9 years (Q1–Q3: 8.2–9.5). 
The incident fatal/nonfatal CVD outcome occurred in 
6216 participants (1.8%), and fatal CVD occurred in 
1656 participants (0.5%).
Incident CVD events occurred more frequently in 
those participants with more adverse risk profiles, in-
cluding more frequently being older, male, smokers, 
and with higher systolic blood pressure, diastolic blood 
pressure, total cholesterol, lower HDL-C and ApoA1, 
and higher LDL-C and ApoB (Table 2). Similar patterns 
were seen for the fatal CVD events (Table VII in the on-
line-only Data Supplement). In Kaplan-Meier curves, lip-
ids and lipoproteins by quintiles had strong univariable 
associations with the incident CVD event (Figure I in 
the online-only Data Supplement). Similar associations 
were seen for fatal CVD, although the separation of the 
survival curves for total cholesterol was less clear (Figure 
II in the online-only Data Supplement).
Multivariable Association of ApoA1 and 
ApoB with Outcomes
In Cox models adjusting for nonlipid classical risk fac-
tors, the shapes of the association of total cholesterol, 
non–HDL-C, and ApoB with risk (HR) of the composite 
CVD outcome were positive, with increases in the gra-
dient of risk at around 220 mg/dL for total cholesterol 
and 1.1g/L for ApoB (Figure 1). The shape of the asso-
ciation of HDL-C and ApoA1 with the risk of CVD was 
inverse (Figure 1). HDL-C and ApoA1 had the strongest 
(inverse) associations with risk of fatal CVD (Figure III 
in the online-only Data Supplement), and the shape 
of the association of total cholesterol with risk of fatal 
CVD was “U-shaped” (Figure III in the online-only Data 
Supplement). Exclusion of the first 2 years of follow-up 
did not substantially attenuate these results (Figure IV in 
the online-only Data Supplement).
After adjustment for classical risk factors, 1 SD increase 
in ApoB (0.23 g/L), LDL-C (31.2 mg/dL), and non–HDL-C 
(39.2 mg/dL) had similar associations with incident CVD 
events (HR, 1.23, 1.20, and 1.21, respectively), as did 
measures of calculated LDL-C (Tables 3 and 4). Associa-
tions for 1 SD increase in HDL-C (14.3 mg/dL) and ApoA1 
(0.27g/L) were also similar (HR, 0.81 [both]) (Tables 3 and 
4). Patterns were similar for those on statins (Tables VIII 
and IX in the online-only Data Supplement). Specifically, 
1 SD increments in ApoB, LDL-C, and non–HDL-C were 
broadly equally associated with subsequent CVD risk (HR, 
1.16, 1.15, and 1.16, respectively). In the discordance 
Table 1. Pearson Correlation Coefficients r (and Age- and Sex-Adjusted r) Between Each Pair of Lipids or Proteins in Those Without Baseline 
Cardiovascular Disease and Not Taking a Statin (n=346 686)





ApoB 0.874 (0.880) 1.000      
Direct LDL-C 0.944 (0.947) 0.957 (0.957) 1.000     
Friedewald LDL-C 0.923 (0.921) 0.911 (0.912) 0.959 (0.958) 1.000    
Martin/Hopkins LDL-C 0.941 (0.942) 0.943 (0.943) 0.985 (0.985) 0.983 (0.983) 1.000   
Non–HDL-C 0.931 (0.939) 0.951 (0.950) 0.976 (0.976) 0.921 (0.923) 0.965 (0.966) 1.000  
ApoA1 0.306 (0.268) −0.074 (−0.090) 0.048 (0.022) 0.103 (0.067) 0.063 (0.034) −0.023 (−0.036) 1.000
HDL-C 0.287 (0.254) −0.098 (−0.110) 0.034 (0.015) 0.129 (0.102) 0.062 (0.040) −0.072 (−0.083) 0.924 (0.910)
Apo indicates apolipoprotein; HDL-C, high-density lipoprotein cholesterol; and LDL-C, low-density lipoprotein cholesterol.
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sensitivity analysis, ApoB had stronger associations with 
CVD than LDL-C and non–HDL-C (Tables X and XI in the 
online-only Data Supplement). There was evidence that 
ApoB and LDL-C measurements were more strongly as-
sociated with risk in men, at younger age, in people who 
smoke, and in those with high triglycerides, although the 
association was still positive in all subgroups (Table XII 
in the online-only Data Supplement). Generally, interac-
tions were less pronounced for HDL-C and ApoA1 (Table 
XII in the online-only Data Supplement).
Prediction of CVD Events in Addition to 
Classical Risk Factors
In a model of CVD prediction, classical risk factors 
without lipids yielded reasonable discrimination (C-
index, 0.7378; 95% CI, 0.7331, 0.7436) (Figure  2). 
Discrimination was improved on the addition of total 
cholesterol and HDL-C (C-index change, 0.0084; 95% 
CI, 0.0065, 0.0104). There was near identical improve-
ment on addition of ApoA1 and ApoB instead of total 
cholesterol and HDL-C (C-index change, 0.0089; 95% 
CI, 0.0069, 0.0109) (Figure 2). However, adding ApoB 
plus ApoA1 to total cholesterol and HDL did not im-
prove discrimination (C-index change, 0.0006; 95% CI, 
−0.00003, 0.0012) (Figure 2). Adding any measure of 
LDL-C or ApoB alone to a model already containing to-
tal and HDL-C also offered no substantial discriminative 
benefit (Figure 2). Remnant cholesterol also did not add 
discrimination once total and HDL-cholesterol were in 
the model (C-index change, −0.0001; 95% CI, −0.0003, 
0.0003). Non–HDL-C was not added to the model, at-
tributable to collinearity with a model already contain-
ing total and HDL-C. There was also no strong evidence 
of improvement in goodness of model fit on addition of 
additional lipids and lipoproteins as measured by Akaike 
Information Criteria and Bayesian Information Criteria 
(Table XIII in the online-only Data Supplement). In analy-
sis of the categorical net reclassification index across the 
7.5% 10-year risk threshold, there was some evidence 
that addition of either total cholesterol and HDL-C or 
ApoB and ApoA1 improved classification, particularly 
among cases (Table XIV in the online-only Data Supple-
ment). However once total cholesterol and HDL-C were 
in the model, addition of any measurement of LDL-C 
or apolipoprotein did not improve classification among 
cases or controls, and the upper end of the 95% CI did 
not exceed 0.51% improvement in any overall model 
(Table XIV in the online-only Data Supplement).
Similarly, in a model of fatal CVD prediction based 
on European SCORE risk factors plus current treatments, 
classical risk factors without lipids yielded a C-index of 
0.7813 in the cohort without baseline CVD and not 
taking a statin (95% CI, 0.7708, 0.7919). Discrimina-
tion was improved on the addition of total and HDL-
C (C-index change, 0.0036; 95% CI, 0.0015, 0.0056). 
There was a similar improvement on addition of ApoA1 
and ApoB (C-index change, 0.0045; 95% CI, 0.0021, 
0.0069) (Figure V in the online-only Data Supplement). 
Adding other lipids or proteins to a model already con-
taining total and HDL-C generally offered no discrimina-
tive benefit for fatal CVD (Figure V in the online-only 
Data Supplement).
In the discordance sensitivity analysis, classical risk 
factors with total cholesterol and HDL-C yielded a C-
index of 0.7444 of the fatal/nonfatal CVD outcome 
(95% CI, 0.7317, 0.7572), which was not improved 
on the addition of ApoA1 and ApoB (change 0.0007; 
95% CI, −0.0011, 0.0024), direct LDL (−0.0001; 95% 
CI, −0.0004, 0.0002), Friedewald LDL-C (−0.0001; 
95% CI, −0.0010, 0.0009), or Martins-Hopkins LDL 
(−0.0002; 95% CI, −0.0008, 0.0005).
In participants taking a statin, classical risk factors 
(including baseline CVD status) also yielded reasonable 
Table 2. Distribution of Baseline Characteristics in UK Biobank 
Participants by Incident Fatal/Nonfatal CVD Status in Those Without 






Age (years) 55.5 (8.1) 59.8 (7.0) <0.001
Sex
  Female 194 896 (57.2%) 2145 (34.5%) <0.001
  Male 145 574 (42.8%) 4071 (65.5%)  
Ethnicity
  White 322 983 (94.9%) 5956 (95.8%) <0.001
  Black 5434 (1.6%) 70 (1.1%)  
  South Asian 4681 (1.4%) 102 (1.6%)  
  Other 7372 (2.2%) 88 (1.4%)  
Smoker
  No 305 788 (89.8%) 5002 (80.5%) <0.001
  Yes 34 682 (10.2%) 1214 (19.5%)  
SBP (mm Hg) 138.7 (19.6) 148.3 (21.0) <0.001
DBP (mm Hg) 82.2 (10.7) 85.8 (11.2) <0.001
Antihypertensive medication 41 219 (12.1%) 1357 (21.8%) <0.001
Diabetes 5663 (1.7%) 246 (4.0%) <0.001
Triglycerides (mg/dL) 149.7 (85.9) 174.6 (95.5) <0.001
Total cholesterol (mg/dL) 227.7 (40.6) 233.9 (42.4) <0.001
ApoB (g/L) 1.06 (0.23) 1.13 (0.24) <0.001
Direct LDL-C (mg/dL) 143.6 (31.2) 150.9 (32.3) <0.001
Friedewald LDL-C (mg/dL) 141.5 (34.4) 147.8 (35.9) <0.001
Martin/Hopkins LDL-C (mg/dL) 143.3 (33.7) 150.6 (35.0) <0.001
Non–HDL-C (mg/dL) 170.7 (39.2) 181.5 (40.9) <0.001
HDL-C (mg/dL) 57.0 (14.3) 52.3 (13.6) <0.001
ApoA1 (g/L) 1.55 (0.27) 1.47 (0.26) <0.001
Apo indicates apolipoprotein; CVD, cardiovascular disease; DBP, diastolic 
blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; and SBP, systolic blood pressure.
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discrimination of the fatal/nonfatal CVD outcome (C-
index, 0.7118; 95% CI, 0.7033, 0.7203). Adding non-
HDL improved discrimination (C-index change, 0.0030; 
95% CI, 0.0012, 0.0048), as did adding ApoB or any 
lipid measure (Figure VI in the online-only Data Supple-
ment). However, adding ApoB or LDL to a model already 
Figure 1. Adjusted association of total cholesterol, ApoB, direct LDL-C, non–HDL-C, calculated LDL-C, HDL-C, and ApoA1 with composite fatal/nonfa-
tal CVD events in those without baseline CVD and not taking a statin. 
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Table 3. Adjusted* Associations of Different Lipid and Lipoprotein Measures with Composite Cardiovascular Disease, by Quintile of the 
Distribution in Those Without Baseline CVD and Not Taking a Statin (n=346 686)
Quintiles




  Mean (SD) 0.76 (0.09) 0.93 (0.04) 1.05 (0.03) 1.18 (0.04) 1.41 (0.14)  
  Range 0.40–0.87 0.87–0.99 1.00–1.10 1.11–1.24 1.25–2.00  
  Events/total 816/69 495 994/69 744 1202/69 088 1349/69 397 1855/68 962  
  Rate per 1000 person years (95% CI) 1.34 (1.25–1.43) 1.62 (1.53–1.73) 1.99 (1.89–2.10) 2.22 (2.11–2.35) 3.09 (2.95–3.23)  
  Adjusted HR (95% CI) 0.83 (0.76–0.91) 0.89 (0.81–0.96) 1 (REF) 1.07 (0.99–1.16) 1.44 (1.34–1.55) <0.001
Direct LDL-C (mg/dL)
  Mean (SD) 102.3 (11.9) 126.0 (4.9) 142.0 (4.5) 158.9 (5.5) 189.4 (17.6)  
  Range 33.5–117.1 117.1–134.2 134.3–149.8 149.9–169.2 169.3–307.8  
  Events/total 887/69 345 1076/69 415 1182/69 282 1378/69 307 1693/69 337  
  Rate per 1000 person years (95% CI) 1.46 (1.37–1.56) 1.77 (1.66–1.88) 1.95 (1.84–2.06) 2.27 (2.16–2.40) 2.80 (2.67–2.94)  
  Adjusted HR (95% CI) 0.87 (0.80–0.95) 0.96 (0.88–1.04) 1 (REF) 1.13 (1.04–1.22) 1.40 (1.30–1.51) <0.001
Friedewald LDL-C (mg/dL)
  Mean (SD) 95.8 (13.5) 121.9 (55.4) 139.3 (4.9) 157.8 (6.1) 191.7 (19.9)  
  Range 8.6–112.1 112.2–130.9 130.9–147.8 147.9–169.1 169.2–334.9  
  Events/total 984/69 338 1109/69 337 1195/69 338 1322/69 336 1606/69 337  
  Rate per 1000 person years (95% CI) 1.62 (1.52–1.73) 1.83 (1.72–1.94) 1.97 (1.86–2.08) 2.18 (2.07–2.30) 1.65 (1.53–2.79)  
  Adjusted HR (95% CI) 0.87 (0.80–0.95) 0.96 (0.88–1.04) 1 (REF) 1.07 (0.99–1.16) 1.32 (1.22–1.42) <0.001
Martin/Hopkins LDL-C (mg/dL)
  Mean (SD) 98.7 (12.9) 124.4 (5.3) 141.6 (4.8) 159.7 (5.9) 192.7 (19.8)  
  Range 26.4–114.6 114.7-113.2 113.3–150.0 150.1–170.5 170.6–333.2  
  Events/total 899/69 338 1127/69 337 1162/69 338 1361/69 336 1667/69 337  
  Rate per 1000 person years (95% CI) 1.48 (1.39–1.58) 1.85 (1.75–1.97) 1.91 (1.81–2.03) 2.24 (2.13–2.37) 2.76 (2.63–2.89)  
  Adjusted HR (95% CI) 0.87 (0.80–0.95) 1.01 (0.93–1.10) 1 (REF) 1.14 (1.05–1.23) 1.42 (1.43–1.53) <0.001
Non–HDL-C (mg/dL)
  Mean (SD) 119.0 (14.3) 148.4 (6.2) 168.5 (5.7) 189.9 (7.0) 228.6 (22.3)  
  Range 41.4–137.1 137.2–158.6 158.7–178.4 178.5–202.9 203.0–409.8  
  Events/total 844/69 350 1014/69 358 1176/69 344 1396/69 300 1786/69 334  
  Rate per 1000 person years (95% CI) 1.39 (1.30–1.49) 1.67 (1.57–1.77) 1.94 (1.83–2.05) 2.30 (2.19–2.43) 2.95 (2.82–3.09)  
  Adjusted HR (95% CI) 0.89 (0.81–0.97) 0.93 (0.86–1.01) 1 (REF) 1.14 (1.05–1.23) 1.45 (1.35–1.57) <0.001
HDL-C (mg/dL) 
  Mean (SD) 39.1 (4.2) 48.2 (2.1) 55.3 (2.1) 63.5 (2.7) 78.7 (8.6)  
  Range 13.4–44.5 44.6–51.7 51.8–59.0 59.1–68.5 68.6–141.4  
  Events/total 1969/69 367 1451/69 423 1131/69 361 928/69 261 737/69 274  
  Rate per 1000 person years (95% CI) 3.26 (3.11–3.40) 2.39 (2.27–2.51) 1.86 (1.75–1.97) 1.53 (1.43–1.63) 1.22 (1.13–1.31)  
  Adjusted HR (95% CI) 1.41 (1.31–1.52) 1.16 (1.08–1.26) 1 (REF) 0.92 (0.83–0.99) 0.78 (0.71–0.85) <0.001
ApoA1 (g/L)
  Mean (SD) 1.21 (0.09) 1.39 (0.04) 1.53 (0.04) 1.67 (0.05) 1.96 (0.17)  
  Range 0.42–1.32 1.32–1.46 1.46–1.59 1.59–1.76 1.76–2.50  
  Events/total 1898/69 581 1406/69 382 1122/69 260 954/69 382 836/69 081  
  Rate per 1000 person years (95% CI) 3.13 (2.99–3.27) 2.31 (2.20–2.44) 1.85 (1.74–1.96) 1.57 (1.47–1.67) 1.38 (1.29–1.48)  
  Adjusted HR (95% CI) 1.48 (1.37–1.59) 1.17 (1.08–1.26) 1 (REF) 0.91 (0.84–1.00) 0.86 (0.77–0.93) <0.001
Apo indicates apolipoprotein; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; HR, hazard ratio; LDL-C, low-density lipoprotein cholesterol; 
Q, quintile; and REF, reference level.
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containing non-HDL did not further improve discrimina-
tion (Figure VI in the online-only Data Supplement).
DISCUSSION
In this large and comprehensive single cohort, we clear-
ly demonstrate that total cholesterol and HDL-C, even 
when measured in the nonfasting state, adequately 
capture conventional lipid-associated cardiovascular 
risk for primary CVD outcomes. Apolipoproteins give 
negligible additional predictive value when they either 
replace total cholesterol and HDL-C or are added on top 
of them. We also show that for people on statins, ApoB, 
direct and measured LDL-C, and non–HDL-C have very 
similar associations with incident CVD, and addition of 
further lipid measurements does not substantially im-
prove non–HDL-C in terms of prediction. We also show 
that while all lipids are broadly linearly related to inci-
dent fatal/nonfatal CVD outcomes, the relationship of 
lipids and lipoproteins to fatal CVD, as used in SCORE, 
is often nonlinear, which may complicate risk prediction 
for scores using only fatal outcomes. Given that all as-
says in UK Biobank were conducted in a single center 
using robust routine assays, these results from over 400 
000 participants add considerable evidence to the lit-
erature. They suggest there is no need for widespread 
measurement of the much more costly apolipoproteins 
or direct LDL-C in usual risk factor screening for CVD 
when cheaper measures of total cholesterol and HDL-C 
are available.
There has been considerable research suggesting 
apolipoproteins may improve CVD risk over measure-
ment of total cholesterol and HDL-C. The INTERHEART 
Table 4. Adjusted* Associations of Different Lipid and Lipoprotein 
Measures With Composite Cardiovascular Disease Using a Linear Model 
in Those Without Baseline CVD and Not Taking a Statin (n=346 686)
Adjusted HR per 1 SD 
Increase P Value
ApoB 1.23 (1.20–1.26) <0.001
Direct LDL-C, 1.20 (1.17–1.23) <0.001
Friedewald LDL-C 1.17 (1.14–1.20) <0.001
Martin/Hopkins LDL-C 1.19 (1.16–1.22) <0.001
Non–HDL-C 1.21 (1.18–1.24) <0.001
HDL-C 0.81 (0.79–0.84) <0.001
ApoA1 0.81 (0.78–0.83) <0.001
Apo indicates apolipoprotein; CVD, cardiovascular disease; HDL-C, high-
density lipoprotein cholesterol; HR, hazard ratio; and LDL-C, low-density 
lipoprotein cholesterol. *Age, sex, ethnicity, systolic blood pressure, diastolic 
blood pressure, antihypertensive medication, diabetes, and smoking.
Figure 2. Change in C-index for prediction of incident fatal/nonfatal CVD on addition or substitution of lipids and apolipoproteins to classical CVD 
risk factors in those with no baseline CVD and not taking a statin. 
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study used apolipoproteins and showed them to be 
strongly predictive of risk; however, this was a case-
control study, which has well-established limitations, 
and the study did not directly compare lipids and apo-
lipoproteins incremental discrimination on addition to 
a risk score containing classical risk factors.26 Individual 
participant meta-analysis suggested that replacement 
of traditional lipid parameters with ApoA1 and ApoB 
measurements only offered modest improvement in 
CVD prediction.13,27 The limitations of that study in-
cluded use of different assays in constituent studies, 
increasing the possibility of exposure misclassification. 
Indeed, despite the Emerging Risk Factor Collaboration 
results, many investigators and guidelines have contin-
ued to recommend measurement of apolipoproteins in 
risk factor assessment.9,14,28,29 Our results broadly fit and 
extend data from Emerging Risk Factor Collaboration 
and are in line with recommendations made by other 
investigators,30 as well as recent clinical guidelines; in-
deed, in these guidelines, it was noted the apolipopro-
teins were not available to all clinicians and were more 
expensive than usual lipid measures.4 Furthermore, a re-
cent study showed that ApoB may be more informative 
than LDL-C in estimating the impact of genetic varia-
tion in lipid processing pathways.31 These data might 
lead to a reinvigoration of arguments for measuring 
ApoB in risk prediction. However, such data cannot 
be extrapolated to the risk prediction environment in 
people in the general population being considered for 
lipid lowering therapy.
We acknowledge that risk prediction metrics in 
the current study do not necessarily inform us about 
the clinical implications of reductions in different lipid 
parameters on treatment.32 However, the use of non–
HDL-C has been suggested as a potential treatment 
target of lipid-lowering therapy in a meta-analysis of 
statin trials.33 In the present UK Biobank study, non–
HDL-C was as strongly associated with incident CVD 
as ApoB and LDL-C for patients on statins, with HRs 
for 1 SD increase being almost identical. The fact that 
non–HDL-C can be performed using nonfasting sam-
ples, and is cheaper to measure, means this should be 
the default measurement to inform treatment deci-
sions in those on statins. However, we accept further 
work is required to raise awareness of non–HDL-C in 
the clinical community and to validate it as a treatment 
target.34 In the discordance analysis, ApoB was more 
strongly associated with CVD than LDL-C or non–HDL-
C, but even in this highly selected subset (18% of the 
main cohort), there was no improvement in discrimina-
tion when apolipoproteins were added to the risk score 
model.
The strengths of our study include the large cohort 
size at an age relevant to CVD risk scoring, biochemistry 
assays performed consistent with the internationally rec-
ognized standard for testing and calibration laboratories, 
and using models with comprehensive adjustment for all 
usual cardiovascular risk factors. We were also able to 
separately analyze participants already on statins as well 
as those with previous CVD. The numbers of events ac-
crued in the study are also considerable in the context 
of existing literature. Passive collection of Hospital Epi-
sode Statistics data has the advantage over active cohort 
studies that loss to follow-up is minimized. The primary 
reason for loss to follow-up here is emigration. Estimates 
suggest that emigration in the UK Biobank cohort is mini-
mal (≈0.3%).35 The use of Hospital Episode Statistics data 
to identify hospitalization for CVD shows reasonable ac-
curacy compared to active biomedical examinations; for 
instance, the sensitivity and specificity for coronary heart 
disease have been reported at 72% and 96%.36,37 Fur-
ther potential limitations include the relatively low aver-
age CVD risk of participants. Even so, baseline risk factors 
were predictive of CVD in the expected manner, and risk 
prediction models performed broadly in line with expec-
tations. We were unable to update participant risk during 
follow-up for new initiation of statin therapy, although 
we did consider those taking statins as a separate group 
and report similar findings, suggesting the influence of 
statins and changes in statin status during follow-up are 
likely to be minimal. Separate studies would be required 
to investigate the utility of different measures of choles-
terol and apolipoproteins in investigating statin efficacy 
on CVD events.38 UK Biobank is not representative of the 
whole UK population, but this is generally not a con-
cern in investigating risk associations.39 Incident events 
were not adjudicated, as they would be in a clinical trial, 
but ascertainment of such events has been in line with 
other cohort studies used to generate risk scores.40,41 The 
C-statistic has been criticized for a lack of sensitivity to 
potentially important clinical changes in predictive util-
ity, but the results of our analysis using the net reclas-
sification index are consistent with increments in the C-
statistic. Finally, as most of the participants were white, 
separate work is needed to validate these findings in dif-
ferent races.
In conclusion, data from UK Biobank show that the 
predictive ability of total cholesterol and HDL-C, in the 
context of other classical risk factors, are not improved 
by the addition or replacement with apolipoproteins in 
the assessment of CVD risk. Similarly, non–HDL-C ap-
pears adequate to assess on-treatment lipid lowering 
therapy in this setting. Although lipoprotein(a) mea-
surements may have a role in some settings, these large 
scale data support the measurement of standard total 
cholesterol and HDL-C in the nonfasting setting as be-
ing perfectly adequate in their capture of lipid-associat-
ed CVD risk and for determining non–HDL-C as a treat-
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